Login
EANO

Corporate Symposia

Corporate Symposia

Corporate Symposium (CS01) | Servier

 

How IDH Inhibition is Transforming The Treatment Sequence for Glioma Patients? From Clinical Trials to Real-Life Practice

Friday, October 17 | 13:30 - 14:30 hrs | South Hall 2, Level 2

13:30 – 13:33

Introduction

Michael Weller – Co-Chair  
Chairman of the Department of Neurology, University Hospital Zurich, Switzerland

13:33 – 13:48

The Daily Burden of mIDH Diffuse Glioma: Exploring the Underestimated Impacts of the Disease

Shawn Hervey-Jumper - Speaker
Neurosurgeon, UCSF Brain Tumor Center, San Francisco, CA, USA

13:48 – 14:03

From INDIGO Study to Clinical Practice: What Have we Learned?

Roberta Rudà – Speaker
Neurologist, University of Turin, Italy 

14:03 – 14:18

What’s Next? Addressing the Unmet Needs of all IDHm Patients and Optimizing Treatment Sequence 

Marjolein Geurts - Speaker
Neuro-Oncologist, Erasmus University Medical Center, Rotterdam, The Netherlands

14:18 – 14:28

Panel Discussion 

All

14:28 – 14:30

Conclusion 

Patrick Wen – Co-Chair 
Director of the Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Corporate Symposium (CS02) | SpringWorks Therapeutics*

 

 

NF1-PN in 2025: Advancing patient options and the continuum of care

Friday, October 17 | 13:30- 14:30 hrs | North Hall, Level 2
13:30 – 13:35

Welcome and objectives

Dr. Said Farschtschi
University Medical Center Hamburg-Eppendorf, Germany

13:35 – 13:40

What is NF1, and what makes it so complex?

Dr. Said Farschtschi
University Medical Center Hamburg-Eppendorf, Germany

13:40 – 13:55

The patient with NF1-PN:  Challenges and unmet needs

Prof. Darren Hargrave
UCL − Great Ormond Street Institute of Child Health, UK

13:55 – 14:10

The evolving treatment landscape of NF1-PN

Dr. Dusica Babovic-Vuksanovic
Mayo Clinic, Rochester, USA

14:10 – 14:20Panel insights and discussion: The NF1-PN continuum
All

14:20 – 14:30Audience Q&A
All

 

*Lunch boxes will be provided to session attendees.